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HIV continues to be one of the biggest problems for the global public health. 
The African region is one of the most affected, accounting for almost two 
thirds of the new infections. Many of them are retroviral medications and 
multi-therapies aiming to stop the viral replication and maintaining 
immunological stability, which fail to guarantee the quality of life or enhance 
the patient's immunity
Ozone has biological properties, among which the antimicrobial and 
modulatory effect on the immune response is highlighted, which makes it 
possible to use it in a complementary way for the treatment of these patients.
We conducted the present study in which the effect of the ozone therapy 
administered systemically (blood route) is analyzed. We have studied 32 
patients to whom we applied Major Autohemotherapy with a protocol of 15 
sessions and maintenance every 15 days at 50 µg/mL of concentration; the 
initial dose was 4,000 µg/mL up to 12,000 µg/mL.
We indicated viral load, CD4 and CD8 counts before and at the end of 
therapy. The results showed a significant decrease in viral load to 
undetectable values and an increase of CD4 and CD8 at the end of the 15 
sessions, being maintained at 2 years of treatment, thus achieving a 
permanent activation of the immune system and improving the quality of life 
of these patients.
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Introduction 
The Human Immunodeficiency Virus (HIV) is a retrovirus. It means that the 
virus genetic material consists of RNA and, once it managed to infect a cell, 
has the ability to convert RNA to DNA, so as to be able to incorporate their 
genetic material into the cells (DNA) in this case directly affecting CD4 
helper T cells.
Currently, HIV continues to be one of the biggest problems for global public 
health, it has already taken over 35 million lives. In 2016, one million people 
died for causes related to this virus. At the end of that year there were 
approximately 36.7 million people infected with HIV worldwide, and 1.8 
million new infections occurred. According to data from 2016, in the WHO 
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most affected and accounts for almost two thirds of new HIV infections in the 
world [1].
In Angola, the adult population incidence rate was 2.7% in 2015 [2].
The HIV / AIDS treatment consists in three main parts: the disease 
preventive treatment, opportunistic diseases treatment and drug treatment. 
Of all of them the preventive treatment is the ideal right now, since there is 
no cure for the disease. The treatment of opportunistic diseases is based on 
the CD4 T cell count, is aimed at treating and preventing them, as well as 
prolonging the patient’s life.
Drug treatment, which encompasses a large number of drugs, mainly the 
use of antiviral drugs such as Reverse Transcriptase (RT) inhibitors, 
analogues as: Zidovudine (AZT), Didanosine (Dd), Zalcitabine, Lamivudine 
(TC), Stavudine (DT), Combivir (Glaxo Operations UK Limited. Priory Street, 
Ware, Herts SG12 0DJ,United Kingdom), Abacavir and no-analogues as: 
Nevirapine, Efavirenz, Delavirdine.
Antiviral agents of the Protease Inhibitors (PI) type. In recent years important 
results have been obtained with this class of antivirals; which are 
characterized by high antiviral activity translating into a marked decrease in 
viral load and an increase in CD4 T lymphocytes. They are used in 
combination with analog reverse transcriptase inhibitors. In this group we 
found: Saquinavir, Ritonavir, Indanavir, Nelfinavir, Atazanavir, Lopinavir / 
ritonavir kaletra. In addition, integrase inhibitors such as Raltegravir, Stribild 
and Dolutegravir are also known.
Similarly, treatments based on Chemokine Coreceptor Antagonists (CCR5) 
have been developed which are targeted against these coreceptors by 
selectively inhibiting the interaction between the human CCR5 receptor and 
the gp120 viral glycoprotein, preventing HIV from entering the cell 
(Maraviroc).
Also known are fusion or entry inhibitors. These inhibit the fusion process of 
the glycoprotein complex gp 120 / gp 41 from the viral envelope to the cell 
membrane, preventing virus penetration (Enfuvirtide). In the case of 
treatments based on fixed combinations (combination of several active 
ingredients in a single tablet or capsule), several drugs have been developed 
as Combivir, Trizivir and Kivexa (Glaxo Operations UK Limited. Priory Street, 
Ware, Herts SG12 0DJ,United Kingdom), Kaletra (AbbVie Inc., 1 North 
Waukegan Rd, North Chicago, IL 60064, USA), Truvada, Atripla, Complera, 
Eviplera and Stribild (Gilead Sciences Inc., 333 Lakeside Drive, Foster City, 
CA 94404,).
The conditions for treatment initiation are:
Evaluation of the CD4 count for initiation of antiretroviral therapy (ARVT):
• Less than 200 cells / mm3: treat regardless of clinical stage.
• From 200-350 cells / mm3: is recommended, because it is considered that 
at this level there is a functional immune deficiency.
• >350-500 cells / mm3: no treatment is recommended; except for some 
special conditions [3].
Despite these advances, there are still factors that limit the achievement of 
good long-term results. In a research protocol (termed ACTG 320 clinical 
trial) the combination of Zidovudine, Lamivudine and Indinavir did not 




Journal of Ozone Therapy,  Vol.2, No.3, 2018:    /  2 9
JO3TJavier Cespedes-Suarez
disease. The same occurred in 50% of patients treated with a regimen based 
on Indinavir or Ritonavir. Because the cross-resistance frequency to all three 
types of antiretroviral drugs (nucleoside and non-nucleoside reverse 
transcriptase inhibitors and protease inhibitors), failure with one regimen 
limits future treatment options. This implies the need to develop new drugs, a 
slowly progressing process [4,5].
Faithful adherence to HIV treatment is not always easy and, in some cases, 
impossible. Side effects and interaction with other medications are common. 
These effects call into question the innocuousness of the newest treatments 
when used for prolonged periods [6].
On the other hand, there are also other natural treatments that perfectly 
complement the pharmacological ones. Multiple references point to ozone 
therapy as an encouraging alternative for HIV-infected patients. Recent 
studies show that, in addition to potentiating the effect of antiretrovirals, it is 
useful in the prevention and treatment of many complications of this disease 
[7,8].
Ozone therapy alone has very significant effects as a modulator of the 
immune system, and oxidative stress. When oxidative stress is small, 
transient and controlled, it restores the antioxidant defense systems needed 
in these seropositive patients who are in chronic oxidative stress [9,10,11].
Ozone increases the production of interferon’s that have the ability to 
interfere in the replication of viruses in host cells. Gamma interferon levels 
can be raised from 400% to 900% with their antiviral activity. They prevent 
viral replication and activate CD4 + T lymphocytes (helper), 
immunomodulatory functions and natural killer cells (cytotoxic). Also induce 
the cytotoxicity of CD8 + T lymphocytes, promotes the proliferation and B 
lymphocytes activation, which is why these cells are considered a 
fundamental pillar in the mediated-cell immune response. The CD4 + T 
lymphocytes activation trigger an immune reactions cascade [12,13]. CD8 + 
T lymphocytes, macrophages, neutrophils, eosinophils, NK cells and the 
activation of antibody-dependent cellular cytotoxicity (ADCC) constitute 
immune effectors mechanisms to destroy virus-infected cells [14]. Previous 
studies have shown different types of ozone treatments against HIV infection 
[15]. Considering this background, the aim of this study is to demonstrate the 
immunological response in HIV-AIDS patients treated with ozone by major 
autohemotherapy during 2 years.
Materials and methods 
A retrospective longitudinal study was performed at the Cardiozono Medical 
Center located in Luanda, Angola. Thirty-two patients with no gender 
distinction were included. They began treatment at the Medical Center in 
August 2015 until August 2017, submitted to our Clinic from an Infectology 
Consultation and other Hospitals, with 1-3 years of seropositive diagnosis.
9 patients were male (28.1%) and 23 (71.9%) were female. The age ranged 
from 32 up to 48 years old. The groups with the highest incidence of disease 
were the ranges 36-45 and 46-55 years. 
Inclusion criteria: HIV positive patients with high viral load and low CD4 
and CD8 counts, under retroviral treatment (Lamivudine 150 mg and 
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Exclusion criteria: HIV positive patients who did not comply with the 
treatment time and serological results expressed in the inclusion criteria. 
Pregnant women and patients under 18 years of age.
Treatment Protocol: The patients received 15 sessions of major 
autohemotherapy (one daily session). In each session we used a German-
made Promedic Humazon equipment (Humares GmbH, Bruchsal, 
Germany), 3-way stopcock, epicranial needle 19 G, Sangiset (Humares 
GmbH, Bruchsal, Germany) with capacity of 350 mL where we put 10 mL of 
3.13% sodium citrate to avoid blood clot during the procedure and other 
disposable material.
The major autohemotherapy (Table 1) was performed at a concentration of 
50 μg / mL in 100 mL of blood; the initial dose of the therapy was 2000 μg 
(40 mL of ozone gas at 50 μg / mL concentration); we increased the dose by 
2000 μg every 2 days until reaching a dose of 12000 μg (240 mL of ozone 
gas at 50 μg / mL concentration), keeping this dose as a maintenance dose 
every 15 days throughout the year. 
Evaluation criteria (before and after treatment): Results of the viral load, 
CD4 and CD8 counts per month and every 6 months, until 2 years of 
therapy.
The real-time PCR reference values were taken into account as a 
standardized method to determine Viral Load with an analytical range of 
50-300,000 copies/mL. This technique was developed in a clinic authorized 
for the diagnosis of this virus
CD4 values with a range of 500-1600 cells/mm3 and CD8 of 375-1100 cells/mm3 
were taken into account according to the reference of the clinical laboratory 
in which these tests were performed.
Statistical analysis: We used SPSS 19.0 statistic software and we 
categorized the values using contingency tables utility and chi-square 
analysis for the significance on the changes before and after the treatment. 
Values of chi-square under 0,05 were considered significant. 
Side effects evaluation: As a marginal target, the increase in the quality of 
life referred by most of the patients and the decrease in the rate of side 
effects made us compile them in an open list way and calculate incidence 
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Table 1: Treatment protocol.
Days of treatment Ozone dose in µg in 100 ml blood  
(concentration and volumen of ozone)
Days 1-2 2000 (50 µg/mL and 40 ml)
Days 3-4 4000 (50 µg/mL and 80 ml)
Days 5-6 6000 (50 µg/mL and 120 ml)
Days 7-8 8000 (50 µg/mL and 160 ml)
Days 9-10 10 000 (50 µg/mL and 200 ml)
Days 11-15 12 000 (50 µg/mL and 240 ml)
Maintenance every 15 days 12 000 (50 µg/mL and 240 ml)
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Results 
Before starting treatment, most patients had a viral load between 
15,000-20,000 IU / ml for 46.9%, and after one month the viral load was 
undetectable in 100% of the sample during the 2 years under treatment 
(Table 2).
The results on the kinetics cell populations of TCD4 and TCD8 are shown in 
Tables 3 and 4. Before starting the treatment, the highest number of patients 
had a CD4 count between 250-300 cells / mm3 for 71.9%. At one month, 
53.1% presented values between 550-600 cells / mm3, reaching the ranges 
between 600-700 and 700-800 cells / mm3 at 6 months, being maintained at 
one and at two years in 100% of patients (Table 3).
In the case of CD8 cells, the highest number of patients had a CD8 count 
between 240-300 cells / mm3 for 81.3%, before starting treatment. At one 
month, 59.4% presented values ranging from 400-450 cells / mm3, to 
500-1000 cells / mm3 at 6 months, and remained within 2 years of treatment 
in 100% of patients (Table 4). 
The patients presented with side effects of antiretroviral therapy are as 
following: 
• Decay
• Lack of appetite,
• Insomnia, 
• Nausea, Headache, 
• Gastric discomfort. 
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Table 2: Viral load behavior in 32 patients treated with ozone therapy at the beginning 
and after 1, 6, 12, 18 and 24 months (2 years) of treatment.























10 000 - 15 000 
UI/mL
8  
(25%) 0 0 0 0 0
15 000 - 20 000 
UI/mL
15 
(46.9%) 0 0 0 0 0
20 000 - 25 000 
UI/mL
9  
(28.2%) 0 0 0 0 0
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Table 3: CD4 behavior in 32 patients treated with ozone therapy at the beginning and 















250-300 23  (71.9%)      
300-350 9  (28.1%)      
450-500  15 (46.9%)*     
550-600  17 (53.1%)*     















Table 4: Behavior of CD8 in 32 patients treated with ozone therapy at the beginning 















240-300 26  (81.3%)

















* chi-square significant value
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Discussion 
The HIV infection evolution is closely related to the immune response, that 
the patient can achieve the effectiveness and control of viral replication. 
There have been different studies that suggest that a cell response mediated 
by helper T cells (CD4), cytotoxic T lymphocytes (CD8) together with NK 
cells predict a favorable prognosis in the control of HIV infection, where there 
is a gradual loss of CD4 lymphocytes because these are the target cells of 
this retrovirus. Likewise, in the immune response to HIV, NK cells play an 
important defensive role due to the CD4 rapid decrease, these NK cells are 
of vital importance because they do not have CD4 receptors and some of 
them are resistant receptors to HIV infection virus. Considering the 
implication of the immune system in the pathogenesis of HIV infection, as 
well as the immunomodulatory effect of ozone therapy on TCD4, TCD8 and 
NK cells, we have evaluated the efficacy of a treatment based on increased 
autohemotherapy against HIV in infected patients [16,17].
Taking into account the values obtained after counting CD4 and CD8 T cell 
populations at 6 months of treatment, as well as the impossibility of detecting 
viral RNA during the first month of treatment and during the two years of this 
study, our results show that the treatment with major autohemotherapy acted 
as a modulator of the immune system and as an enhancer of current 
antiretroviral therapy. It is important to note that the treatment employed was 
able to maintain undetectable viral load during the two years of treatment, 
resulting in a potentiating effect on the number of T cells (CD4 and CD8) 
during this time. Our results are similar to those previously obtained by 
Gonzalez et al., 2003 [18], and Méndez et al., 2005 [15], although in Mendez 
study, ozone treatment was administered rectally. This can be an option 
when major autohemotherapy can`t be performed and the results are the 
same20 adjusting the dosification. Due to cultural reasons in Angola, rectal 
insufflation is usually refused.
We must also point out an important aspect, HIV infection causes oxidative 
stress in these patients, this is because in their pathogenesis and evolution, 
reactive oxygen species (ROS) may be involved. The oxidative stress acts 
on the immune system, producing a decrease in the intracellular antioxidant 
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Improvement          Disappearance
decay 32 (100%) 32 (100%)*
lack of appetite 32 (100%) 32 (100%)*
insomnia 32 (100%) 32 (100%)*
gastric discomfort 30 (93,75%) 7 (21,88%)* 23 (71,87%)*
nausea 28 (87,5%) 4 (12,5%)* 24 (75%)*
headache 20 (62,5%) 6 (18,75%)* 14 (43,75%)*
* chi-square significant value
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immune system (for example TCD4 cells)21. The induction of an oxidative 
stress with medical ozone, through controlled treatments (for example, main 
autohemotherapy) stimulates the endogenous antioxidant systems that 
control the excessive production of ROS, by Diaz L. et al., 2018 [22], thus 
supporting the activation of the system through the decrease as a 
consequence of the apoptosis of the TCD4 cells, which in turn are attacked 
by the virus.
Conclusions 
Our results support previous studies that demonstrate the immunomodulatory 
potential of ozone, as well as the beneficial effect of ozone therapy at the level 
of the immune system, in the control of oxidative stress and its relationship 
with the immune response that improves HIV infection. Considering that there 
is not much information in the scientific literature on this type of strategies, this 
work provides information on the immunomodulatory capacity of ozone against 
one of the most relevant infections in human health that does not yet have an 
effective treatment.
No side effects were presented because of the ozone treatment. The quality of 
life improved not only because the improvement of the immunological status 
but also thanks to the decrease of antiretroviral therapy side effects.
We recommend carrying out studies with a greater number of patients, 
including other parameters to be studied, so that the introduction of ozone 
therapy in HIV-AIDS treatment protocols could be considered in the future.
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